SHANGHAI, China -- WuXi Biologics ("WuXi Bio") (2269.HK), a
leading global open-access biologics technology platform company offering end-to-
end solutions for biologics discovery, development and manufacturing, has stepped
up its efforts in enabling the development of multiple neutralizing antibodies for
Novel Coronavirus (2019-nCoV) with its integrated technology platforms. These
antibodies from global biotech companies are potent in neutralizing 2019-nCoV in
preliminary studies.

WuXi Biologics has established a 100+ R&D team dedicated to the development and
manufacturing of multiple neutralizing antibodies for 2019-nCoV. The first batch of
antibody is expected to be produced in 2 months, ready for preclinical toxicology
studies and initial human clinical studies. Large scale manufacturing will be initiated
following the studies at the company's four GMP facilities with single batch
bioreactor capacity ranging from 2,000 to 12,000 liters. A single batch at this scale
combined is expected to treat up to 80,000 patients.

Confronted by this severe outbreak, WuXi Biologics has taken prompt actions to
accelerate the development of multiple neutralizing antibodies for 2019-nCoV,
based on our extensive biologics development and manufacturing experience in the
fields of infectious diseases. Compared with the traditional timeline of 12 to 18
months, all studies from DNA to IND could hopefully be completed in 4-5 months
while maintaining high quality. This way we can provide effective and timely
interventions for the disease caused by 2019-nCoV," said Dr. Chris Chen, CEO of
WuXi Biologics. "Continuing in our mission of 'enabling global partners and
benefiting patients worldwide', WuXi Biologics will actively work together with
global and domestic biotechnology companies, hospitals, medical institutions and
other parties to win the battle against this infectious disease."
Enabled by the proprietary technology platforms at WuXi Biologics, all preclinical
CMC for the world's first yellow fever antibody and world's first Zika virus antibody
were completed in a record timeline of 7 and 9 months, respectively.

For more information on WuXi Biologics, please visit
www.wuxibiologics.com.
Media Contact
WuXi Biologics
Jia Li
li_jia0102@wuxiapptec.com